Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19
NCT ID: NCT04505709
Last Updated: 2020-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-08-01
2021-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of COVID-19 Prognostic Factors in Hospitalized Patients
NCT05102708
Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19
NCT04648709
Host-pathogen Interactions During SARS-CoV-2 Infection
NCT04376476
Human Ab Response & immunoMONItoring of COVID-19 Patients
NCT04373200
Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19
NCT04495101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
WP 3 (Dr Ayuso García) is aimed to analyze the genetic markers of host susceptibility associated with clinical evolution of COVID-19.
WP 6 (Dr Ruiz Hornillos) will study the socio-economic and bioethical repercussions of COVID-19.
WP 7 (Dr Perales) will analyze the complexity of the spectrum of SARS-CoV-2 mutants and their possible association with the evolutionary course of COVID-19
This project will guide and individualize the clinical and therapeutic approach to COVID-19 and mitigate the health and social impact of the pandemic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitario 12 de Octubre
OTHER
Fundacion Investigacion Biomedica Hospital 12 de Octubre
UNKNOWN
Hospital Universitario Fundación Jiménez Díaz
OTHER
Hospital Universitario Infanta Elena
UNKNOWN
Hospital Universitario Virgen de la Arrixaca
OTHER
Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca
OTHER
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundacion Jimenez Diaz
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COV20/00181
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
STOP-Coronavirus
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.